Osisko Announces TSX Approval to Renew Normal Course Issuer Bid

MONTREAL, Dec. 10, 2020 (GLOBE NEWSWIRE) — Osisko Gold Royalties Ltd (OR:TSX & NYSE) (the “Corporation” or “Osisko“) today announces that the Toronto Stock Exchange (the “TSX“) has approved the Corporation’s notice of intention to make a normal course issuer bid (the “NCIB Program“). Under the terms of the NCIB Program, Osisko may acquire up to 14,610,718 of its common shares (“Common Shares“) from time to time in accordance with the normal course issuer bid procedures of the TSX.

The normal course issuer bid will be conducted through the facilities of the TSX or alternative trading systems, if eligible, and will conform to their regulations. Purchases under the normal course issuer bid will be made by means of open market transactions or such other means as a securities regulatory authority may permit, including pre-arranged crosses, exempt offers and private agreements under an issuer bid exemption order issued by a securities regulatory authority.

Repurchases under the NCIB Program may commence on December 12, 2020 and will terminate on December 11, 2021 or on such earlier date as the NCIB Program is complete. Daily purchases will be limited to 138,366 Common Shares, other than block purchase exemptions, representing 25% of the average daily trading volume of the Common Shares on the TSX for the six-month period ending November 30, 2020, being 553,464 Common Shares.

The price that the Corporation may pay for any Common Shares purchased in the open market under the NCIB Program will be the prevailing market price at the time of purchase (plus brokerage fees) and any Common Shares purchased by the Corporation will be cancelled. In the event that the Corporation purchases common shares by pre-arranged crosses, exempt offers, block purchases or private agreements, the purchase price of the common shares may be, and will be in the case of purchases by private agreements, as may be permitted by the securities regulatory authority, at a discount to the market price of the common shares at the time of the acquisition.

The board of directors of Osisko believes that the underlying value of the company may not be reflected in the market price of the Common Shares from time to time and that, accordingly, the purchase of Common Shares will increase the proportionate interest in the company of, and be advantageous to, all remaining shareholders of the Corporation.

As of November 30, 2020, there were 166,893,334 Common Shares issued and outstanding. The 14,610,718 Common Shares that may be repurchased under the NCIB Program represent approximately 10% of the public float of the Corporation as of November 30, 2020, being 146,107,180 Common Shares.

During the prior NCIB Program of the Corporation, which will end on December 11, 2020, the Corporation obtained approval to purchase 13,681,732 Common Shares and actually purchased 429,722 Common Shares at a weighted average price of approximately $9.15 per Common Share through the facilities of the TSX.

Osisko has appointed Desjardins Capital Markets to make any purchases under the NCIB Program on its behalf.

About Osisko Gold Royalties Ltd

Osisko Royalties is an intermediate precious metal royalty company focused on the Americas that commenced activities in June 2014. Osisko Royalties holds a North American focused portfolio of over 135 royalties, streams and precious metal offtakes. Osisko Royalties’ portfolio is anchored by its cornerstone asset, a 5% net smelter return royalty on the Canadian Malartic mine, which is the largest gold mine in Canada.

Osisko’s head office is located at 1100 Avenue des Canadiens-de-Montréal, Suite 300, Montréal, Québec, H3B 2S2.

For further information, please contact
Osisko
Gold Royalties Ltd:

Sandeep Singh
President
Tel. (514) 940-0670
[email protected]
 

Forward-looking statements

This press release contains forward-looking statements. These forward-looking statements, by their nature, require the Corporation to make certain assumptions and necessarily involve known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in these forward-looking statements.
Words such as “may”, “will”, “would”, “could”, “expect”, “believe”, “plan”, “anticipate”, “intend”, “estimate”, “continue”, or the negative or comparable terminology, as well as terms usually used in the future and the conditional, are intended to identify forward-looking statements including the fact that the Corporation “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential”, “scheduled” and similar expressions or variations (Including negative variations), or that events or conditions “will”, “would”, “may”, “could” or “should” occur including, without limitation, statements about the board of directors of
Osisko’s
belief that the NCIB Program is advantageous to shareholders and that underlying value of the Corporation may not be reflected in the market price of the Common Shares,
and about
the Corporation’s intentions regarding the NCIB Program
, including the number of Common Shares that may be purchased under
the NCIB Program.
Although
Osisko
believes
the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements involve known and unknown risks, uncertainties and other factors and are not guarantees of future performance and actual results may accordingly differ materially from those in forward looking statements.
Factors that could cause the actual results to differ materially from those in forward-looking statements include, without limitation: fluctuations in the prices of the commodities that drive royalties
, streams and offtakes
held by
Osisko
; fluctuations in the value of the Canadian dollar relative to the U.S. dollar; regulatory changes by national and local government, including corporate law, permitting and licensing regimes and taxation policies; continued availability of capital and financing and general economic, market or business conditions; business opportunities that become available to, or are pursued by
Osisko
; the impossibility to acquire royalties and to fund precious metal streams; other uninsured risks.
The forward looking statements contained in this press release are based upon assumptions management believes to be reasonable, including, without limitation: the ongoing operation of the properties in which
Osisko
holds a royalty or other interest by the owners or operators of such properties in a manner consistent with past practice; the accuracy of public statements and disclosures made by the owners or operators of such underlying properties; no material adverse change in the market price of the commodities that underlie the asset portfolio; no adverse development in respect of any significant property in which
Osisko
holds a royalty or other interest and the absence of any other factors that could cause actions, events or results to differ from those anticipated, estimated or intended.

For additional information with respect to these and other factors and assumptions underlying the forward

looking statements made in this press release, see the section entitled “Risk Factors” in the most recent Annual Information Form of
the Corporation,
which is filed with
(
i
)
the
securities regulatory authorities in Canada
and available electronically under
Osisko’s
issuer profile on SEDAR at

www.sedar.com

,
and
(ii)
the U.S. Securities and Exchange Commission and available electronically under
Osisko’s
issuer profile on EDGAR at

www.sec.gov

.
The forward

looking information set forth herein reflects
Osisko’s
expectations as at the date of this press release and is subject to change after such date.
Osisko
disclaims any intention or obligation to update or revise any forward

looking statements, whether
as a result
of new information, future events or otherwise, other than as required by law.



Supersapiens Gives Athletes Visibility Into Glucose, Redefines Fueling in Sport

In partnership with Abbott, the new ecosystem is available now in select European Markets

ATLANTA, Dec. 10, 2020 (GLOBE NEWSWIRE) — For any human, proper glucose management can mean the difference between feeling good or feeling lackluster. For athletes, the stakes are even higher: Dial in your optimal fuel intake and you can feel strong, fast, and agile in athletic situations. On the other hand, get it wrong — eat too much of the wrong thing or too little of the right thing — and your body could rebel, leaving you out of energy and out of the competition — a worst-case scenario.

Supersapiens, utilizing the Abbott Libre Sense Glucose Sport Biosensor, is the first over-the-counter energy management ecosystem that can give any athlete real-time visibility into their glucose levels, allowing them to fine-tune fueling strategies before, during, and after training and racing. This advancement in sports science stands to eliminate a major variable from race preparation and execution, helping athletes feel more confident on the start line, and ensuring that they have continuous guidance on how to fuel during an event.

Supersapiens Founder and CEO Phil Southerland said “I’ve been an athlete for as long as I can remember and through my own obsession with training and racing, I learned that I was a stronger, faster, better version of myself when I kept my glucose within my optimal range. At the same time, when it went outside of my optimal range, I couldn’t perform at the same level. Getting to bring this same knowledge, to the general athletic population is a dream come true. Everyone’s minds are about to be illuminated by the correlation between proper glucose management and sustained peak performance.”

The Supersapiens ecosystem is powered by and includes the Abbott Libre Sense Sport Biosensor, the Supersapiens App, and a reader that displays data from the biosensor in real-time. The app tracks glucose data in real-time and allows athletes to create events — workouts, meals, rest — so they can see how various glucose levels impact racing and training. The app’s Learn Hub features educational information that helps athletes better understand glucose and the impact it has on performance and learn how to optimize fueling strategies for sustained performance in a variety of sporting events.

CE marked in September, Supersapiens is quickly becoming a must-have piece of training technology for athletes at the highest level of sport. Team Jumbo-Visma, the INEOS Grenadiers, and Canyon//SRAM pro tour teams are all finding success with Supersapiens, including the INEOS Grenadiers’ win at the Giro d’Italia and Team Jumbo-Visma’s second consecutive win at the Vuelta a España after training with the ecosystem. The BMC-Vifit Pro Triathlon Team is the first top-level multi-sport team to track their glucose during training and racing.

The impact and benefits of glucose on endurance sports have been researched and understood for some time but real-time glucose visibility is only now available to athletes through the Abbott Libre Sense Glucose Sport Biosensor. Through a partnership with global healthcare leader Abbott, Supersapiens is able to make this key new performance metric available to athletes looking to improve their performance through glucose visibility.

The science behind Supersapiens has been evaluated and supported by some of the world’s leading sport and performance researchers, including Asker Jeukendrup (PhD), former head of the Gatorade Sports Science Lab, as well as leading endocrinological and performance researchers Juan Pablo Frias (MD), Chief Science Officer, and Federico Fontana (PhD), Vice President for Scientific Affairs.

The Supersapiens Ecosystem and the Abbott Libre Sense Glucose Sport Biosensor is available now in select European markets at Supersapiens.com.

About Supersapiens

Supersapiens is an Atlanta-based sports technology company focused on energy management systems to empower sustained peak performance. Supersapiens empowers athletes to show up to the starting line optimally fueled, manage in-race fueling to sustain peak performance, and guide refueling and recovery.

The Abbott Libre Sense Glucose Sport Biosensor is intended for athletes to measure glucose. Athletes are defined as individuals who perform exercise with the purpose of improving wellness and performance. When used with a compatible product, the biosensor allows athletes to correlate their glucose levels and their athletic performance. The biosensor is not intended for use in the diagnosis, treatment, or monitoring of a disease.
The Supersapiens ecosystem, including the Abbott Libre Sense Glucose Sport System, is not available for sale in the U.S.

Contact Info:

Fitzalan Crowe
[email protected]
703-596-2020

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/dfd4e869-40f6-476f-92f2-2180be0d6093



Norwood Financial Corp Increases Cash Dividend

HONESDALE, Pa., Dec. 10, 2020 (GLOBE NEWSWIRE) — Lewis J. Critelli, President and Chief Executive Officer of Norwood Financial Corp (NASDAQ Global Market – NWFL) and its subsidiary Wayne Bank, announced that the Board of Directors declared a $0.26 per share quarterly dividend payable February 1, 2021 to shareholders of record as of January 15, 2021. The $0.26 per share represents an increase of 4.0% over the cash dividend declared in the prior quarter of this year and the fourth quarter of last year. During 2020, total cash dividends declared were $1.01 per share, compared to the $0.97 declared in 2019.

Mr. Critelli commented, “The Board is extremely pleased to provide our shareholders with this 4.0% increase in their quarterly dividend. It reflects the Company’s financial strength and strong capital position which has contributed to our solid performance. We are also very proud that 2020 marks the twenty-ninth consecutive year of dividend increases for the Company.”

Norwood Financial Corp, through its subsidiary, Wayne Bank, operates fifteen offices in Northeastern Pennsylvania and sixteen offices in Delaware, Sullivan, Ontario, Otsego and Yates Counties, New York. As of September 30, 2020, the Company had total assets of $1.842 billion, loans outstanding of $1.415 billion, total deposits of $1.516 billion and total stockholders’ equity of $190.5 million. The Company’s stock is traded on the Nasdaq Global Market under the symbol “NWFL”.

Forward-Looking Statements. The foregoing material may contain forward-looking statements. We caution that such statements may be subject to a number of risks and uncertainties which may cause actual results to differ materially from those currently anticipated, and therefore readers should not place undue reliance on any forward looking statements. Those risks and uncertainties include, but are not limited to, our ability to pay or increase cash dividends in the future, the continued financial strength, solid performance and strong capital position of the Company, changes in federal and state laws, changes in the absolute and relative levels of interest rates, the potential adverse impact the COVID-19 pandemic may have on Norwood’s financial condition and results of operations, the ability to control costs and expenses, demand for real estate, costs associated with cybercrime, general economic conditions and the effectiveness of governmental responses thereto. Norwood Financial Corp. does not undertake and specifically disclaims any obligation to publicly release the results of any revisions that may be made to any forward-looking statements to reflect the occurrence of anticipated or unanticipated events or circumstances after the date of such statements.

CONTACT:   William Lance
    Executive Vice President and Chief Financial Officer
    NORWOOD FINANCIAL CORP
    (570) 253-8505
    www.waynebank.com



Acuity Brands To Announce Fiscal 2021 First Quarter Results on January 7, 2021

Atlanta, Dec. 10, 2020 (GLOBE NEWSWIRE) — Acuity Brands, Inc. (NYSE: AYI) will host a conference call on Thursday, January 7, 2021, at 10:00 a.m. (EST) to discuss the Company’s performance for the first quarter of fiscal 2021, following the announcement of those results earlier that day.  Neil M. Ashe, President and Chief Executive Officer of Acuity Brands, will lead the call.  A live Webcast of the discussion will be accessible at the Company’s Website:  www.acuitybrands.com.  A replay of the call will also be posted to that site within two hours of the completion of the conference call and will be archived on the site. 

Ab
out Acuity Brands  

Acuity Brands, Inc. (NYSE: AYI) is a market-leading industrial technology company. We design, manufacture, and bring to market innovative products and services that make the world more brilliant, productive, and connected including building management systems, lighting, lighting controls, and location-aware applications.  Based in Atlanta, Georgia, with operations across North America, Europe, and Asia, we are powered by approximately 11,000 dedicated and talented associates. Visit us at www.acuitybrands.com.

#  #  #  #  #


Company Contact:                                      

Pete Shannin             
Acuity Brands, Inc.    
(770) 860-2873                      
[email protected]



II-VI Incorporated to Present at MKM Partners Virtual Conference

PITTSBURGH, Dec. 10, 2020 (GLOBE NEWSWIRE) — II-VI Incorporated (Nasdaq: IIVI), a global leader in engineered materials and optoelectronic components, today announced that the Company will present at the following upcoming investor conference:

MKM
Partners Virtual Conference

  • Date:  Wednesday, December 16, 2020
  • Time:  11:50 a.m. ET
  • Place:  Virtual

Participants

  • Dr. Chuck Mattera, Chief Executive Officer, II-VI
  • Mary Jane Raymond, Chief Financial Officer, II-VI

A real-time audio webcast of the presentation can be accessed via the Investors section of the II-VI website at https://www.ii-vi.com/investors-events/. A replay of the webcast will be available on the Company’s website following the conclusion of the event.


About II-VI Incorporated

II-VI Incorporated, a global leader in engineered materials and optoelectronic components, is a vertically integrated manufacturing company that develops innovative products for diversified applications in communications, materials processing, aerospace & defense, semiconductor capital equipment, life sciences, consumer electronics, and automotive markets. Headquartered in Saxonburg, Pennsylvania, the Company has research and development, manufacturing, sales, service, and distribution facilities worldwide. The Company produces a wide variety of application-specific photonic and electronic materials and components, and deploys them in various forms, including integrated with advanced software to support our customers. For more information, please visit us at www.ii-vi.com.

CONTACT: Mark Lourie
  Vice President, Corporate Communications
  [email protected]
 
www.ii-vi.com/contact-us



Sodexo joins CDP’s A List of global climate change leaders with key progress on its carbon strategy

Sodexo joins CDP’s A List of global climate change leaders with key progress on its carbon strategy

Paris, December 10, 2020 – On the occasion of the 5th anniversary of the Paris Agreement, Sodexo, world leader in Quality of Life Services, has secured a place on the global environmental non-profit Carbon Disclosure Project’s ‘A list’ of climate change leaders’.

For the first time, Sodexo scored an “A” grade, joining 270 high-performing companies out of more than 9,500. This recognition demonstrates key progress on its carbon strategy which includes a target aligned with the most ambitious goal of the Paris Agreement to limit global warming to 1.5°C above pre-industrial levels, as well as concrete actions to cut emissions and transparency in reporting.

“Sodexo is the only company from the foodservices and facility management sectors to be part of this exclusive list of corporate sustainability leaders. This clear testimony to the efforts our teams are deploying alongside our suppliers and clients encourages us on our path towards fundamentally sustainable services,” said Maria Outters, Senior Vice President, Corporate Responsibility at Sodexo. “We are progressing in several areas of our carbon strategy, in line with our science-based and industry-leading target to reducing our total carbon emissions by 34% by 2025.”

Since 2017, Sodexo reduced its Scopes 1 and 2 carbon emissions by 15.9% and its Scope 3 Supply Chain carbon emissions by 10.5%*.

“The partnership between WWF and Sodexo on its carbon strategy over the last 10 years is showing results, and WWF is heavily invested in supporting Sodexo’s transformation and driving sustainable change within the foodservices sector”, said Marie-Christine Korniloff, Deputy Director for Economic affairs, WWF FRANCE. “The entrance of Sodexo in the CDP ‘A-list’ for Climate highlights the commitment of the Group in delivering progress on the reduction of its environmental impact, despite a challenging economic situation.”

Sodexo carbon strategy is built on four key actions:


  1. Fighting food waste with WasteWatch

    WasteWatch, Sodexo’s game-changing food waste prevention program has an ambitious objective of reducing food waste on our sites by 50% by 2025, through measurement and prevention. As the most comprehensive program in the foodservices sectors, Sodexo helped its clients and the consumers served avoid 2,468 tons of food being waste – more than 17,000 tons of carbon since the program started.


  2. Promoting plant-based meal options

    Sodexo has increased its menu mix target for plant-based meals to more than 30% globally to address the growing consumer demand for sustainable food and more natural, local and healthy ingredients. In 6,500 sites in 13 countries, Sodexo also offers menus based on “Future 50 Foods”, which are nutritious and have a lower environmental impact.


  3. Building a low-carbon supply chain

    With 49% of its emissions being linked to its supply-chain, Sodexo is working with suppliers and partners such as the WWF to build a more local and low-carbon supply chain. Sodexo has committed to a deforestation-free and conversion-free supply chain globally by 2030 for the following priority commodities: palm oil, soy, beef and paper products.


  4. Focusing on energy management and renewable energies

    Sodexo has committed to switching to 100% renewable electricity by 2025 at its directly operated sites. Sodexo is also supporting clients in this respect, through Sodexo’s energy management service that generates significant savings and significant returns on investment.

Partnering to act on climate change is part of the positive impact of doing business with Sodexo.

*More information on Sodexo’s reduction in carbon emissions are available on page 78 of the company’s Fiscal 2020 Universal Registration Document.


About the CDP A List

CDP’s annual environmental disclosure and scoring process is widely recognized as the gold standard of corporate environmental transparency. A detailed and independent methodology is used by CDP to assess responding companies, allocating a score of A to D- based on the comprehensiveness of disclosure, awareness and management of environmental risks and demonstration of best practices associated with environmental leadership, such as setting ambitious and meaningful targets.
The full list of companies that made this year’s CDP A List is available here, along with other publicly available company scores: https://www.cdp.net/en/companies/companies-scores


About Sodexo

Founded in Marseille in 1966 by Pierre Bellon, Sodexo is the global leader in services that improve Quality of Life, an essential factor in individual and organizational performance. Operating in 64 countries, Sodexo serves 100 million consumers each day through its unique combination of On-site Services, Benefits & Rewards Services and Personal & Home Services. Sodexo provides clients an integrated offering developed over more than 50 years of experience: from foodservices, reception, maintenance and cleaning, to facilities and equipment management; from services and programs fostering employees’ engagement to solutions that simplify and optimize their mobility and expenses management, to in-home assistance, child care centers and concierge services. Sodexo’s success and performance are founded on its independence, its sustainable business model and its ability to continuously develop and engage its 420,000 employees throughout the world.
Sodexo is included in the CAC Next 20, ESG 80, FTSE 4 Good and DJSI indices.

Key figures

19.3 billion euro in Fiscal 2020 consolidated revenues
420,000 employees as at August 31, 2020
N°1 France-based private employer worldwide
64 countries
100million consumers served daily
8.1 billion euro in market capitalization (as at October 28, 2020)

Contact

Media
Tugdual HOUEX

Tel: +33 1 57 75 85 46
[email protected]

 

Attachment



IIROC Trading Halt – CKG

Canada NewsWire

VANCOUVER, BC, Dec. 10, 2020 /CNW/ – The following issues have been halted by IIROC:

Company: Chesapeake Gold Corp.

TSX-Venture Symbol: CKG

All Issues: Yes

Reason: At the Request of the Company Pending News

Halt Time (ET): 8:02 AM

IIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. IIROC is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada.

SOURCE Investment Industry Regulatory Organization of Canada (IIROC) – Halts/Resumptions

ENGIE announces 650 MW of renewable energy offtake contracts with Amazon

PR Newswire

HOUSTON, Dec. 10, 2020 /PRNewswire/ — Today, ENGIE announces several energy offtake contracts with Amazon for a global renewable energy portfolio of wind and solar projects across the United States, Italy and France totaling 650 MW. These Corporate Power Purchase Agreements (PPAs) will exclusively rely upon renewable energy production facilities developed by ENGIE. For ENGIE, this operation is the largest portfolio of agreements signed at once with a single counterparty.

These projects align with Amazon’s goal to power its operations with 100% renewable energy by 2030 and reach net zero carbon by 2040. They also demonstrate ENGIE’s expertise across the green energy value chain, from the construction and operation of renewable energy plants, to the sale of energy to industrial customers. In 2019, ENGIE was the #1 global seller of clean energy Corporate PPAs and signed over 2,000 MW mostly in the US but also in Europe, notably in Spain.

In the United States, Amazon’s new renewable energy solar and wind projects with ENGIE represent 569 MW in Delaware, Kansas, North Carolina, Ohio and Virginia. They will supply Amazon with approximately 1,850 GWh of power and with the associated project renewable energy credits (REC’s) annually. During construction, ENGIE will create approximately 300 jobs at each wind facility and 210 jobs at each solar facility. Projects are expected to reach commercial operation in 2021 through 2022.

In Europe, Amazon’s total contracts with ENGIE add up to 66 MW in Italy and 15 MW in France, and are the company’s first utility-scale renewable energy projects in each country. Amazon will purchase renewable energy from two solar facilities located in Southern Italy and another in Southern France to power its European operations.  

“These new projects with ENGIE represent our first utility-scale renewable energy projects in Italy and France in Europe and our first projects in Delaware and Kansas in the United States. They substantially help us on our path to powering our operations with 100 percent renewable energy by 2030,” said Nat Sahlstrom, Director, Amazon Energy. “Working with ENGIE, we are able to add 650 MW of new power to grids in the US and Europe. Our push for more renewable energy is one step toward our goal of reaching net-zero carbon by 2040 as part of Amazon’s commitment to The Climate Pledge.”

“These contracts demonstrate ENGIE’s capabilities to commercialize green energy internationally for our customers. And in North America – as elsewhere – we recognize that bold commitments are needed from global companies and local communities alike to lead the way to clean energy use,” said Gwenaëlle Avice-Huet, ENGIE’s Executive Vice President in charge of the Renewables Business Line and CEO of ENGIE North America. “We are excited to work with Amazon to create a clean, prosperous, low carbon future – and create economic benefits for the communities involved.”

About ENGIE 
Our group is a global leader in low-carbon energy and services. Our goal is to accelerate the transition towards a carbon-neutral world by reducing power consumption and providing the most environmentally aware solutions, combining financial profitability with a positive impact on people and the planet. We apply our key businesses (gas, renewable energy, services) to provide competitive solutions for our clients. Our 170,000 employees, clients, partners and stakeholders represent a community of Imaginative Builders, committed to a more balanced daily progress.

Business volume in 2019: €60.1 billion. The group is listed in the Paris and Brussels (ENGI) exchanges and is also included in the top financial indices (CAC 40, DJ Euro Stoxx 50, Euronext 100, FTSE Eurotop 100, MSCI Europe), as well as non-financial indices (DJSI World, DJSI Europe and Euronext Vigeo Eiris – World 120, Eurozone 120, Europe 120, France 20, CAC 40 Governance).

About ENGIE North America
ENGIE North America Inc. offers a range of capabilities in the United States and Canada to help customers decarbonize, decentralize and digitalize their operations. These include comprehensive services to help customers run their facilities more efficiently and optimize energy and other resource use and expense; clean power generation; energy storage; and retail energy supply that includes renewable, demand response, and on-bill financing options. Nearly 100% of the company’s power generation portfolio is low carbon or renewable. Globally, ENGIE S.A. relies on their key businesses (gas, renewable energy, services) to offer competitive solutions to customers. With 170,000 employees, customers, partners and stakeholders, we are a community of Imaginative Builders, committed every day to more harmonious progress. For more information on ENGIE North America, please visit our LinkedIn page or Twitter feed, www.engie-na.com and www.engie.com.

Amazon Media Contact:

[email protected] 

ENGIE North America Media Contact:

Sandrine Deparis, [email protected], (202) 855 3705

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/engie-announces-650-mw-of-renewable-energy-offtake-contracts-with-amazon-301190399.html

SOURCE ENGIE North America

Fusion Pharmaceuticals Initiates Multi-Dose Portion of Phase 1 Trial of FPI-1434 in Patients with Advanced Solid Tumors

PR Newswire

Phase 1 Single-Dose Data Show Uptake Across Multiple Tumor Types; No Dose Limiting Toxicities or Treatment-Related Serious Adverse Events

HAMILTON, ON and BOSTON, Dec. 10, 2020 /PRNewswire/ — Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the first patient has been dosed in the multi-dose portion of the Phase 1 study evaluating [225Ac]-FPI-1434 (FPI-1434) in patients with advanced solid tumors. FPI-1434 is a radioimmunoconjugate that utilizes Fusion’s proprietary Fast-Clear™ linker to connect a humanized monoclonal antibody targeting the insulin-like growth factor 1 receptor (IGF-1R), with the alpha-emitting isotope actinium-225, creating a targeted alpha therapy (TAT).

The Phase 1, multi-center, open-label clinical trial is designed to investigate the safety, tolerability and pharmacokinetics of FPI-1434 in patients with solid tumors expressing IGF-1R.  The trial is also designed to establish the maximum tolerated dose for FPI-1434 and the recommended Phase 2 dose. As part of the precision medicine approach, prior to receiving the therapeutic injection of FPI-1434, patients are administered an indium-111 imaging analogue, [111In]-FPI-1547 (FPI-1547). The images collected are used to confirm the presence of tumor uptake and to ensure that estimated radiation doses to organs and tissues are below protocol-specified safety limits.

The multi-dose study follows completion of the single-dose portion of the Phase 1 study, which showed that FPI-1434 was generally well tolerated with no dose limiting toxicities or treatment-related serious adverse events reported to date. The multi-dose portion of the study is expected to enroll patients at sites in Canada, the United States and Australia. The initial patient cohort is being dosed with FPI-1434 at 75kBq/kg with repeat cycles every six weeks up to allowable limits.

“We are pleased with the results of the single-dose portion of our Phase 1 study of FPI-1434 which, following the evaluation of the Safety Review Committee, support initiating the multi-dosing portion of the study,” said Chief Executive Officer John Valliant, Ph.D. “This is a critical next step in the FPI-1434 development program as data from the multi-dose portion of the study may provide important insights on potential anti-tumor activity. The multi-dosing trial will also inform the design of the Phase 2 program and assist in the selection of tumor indications to be pursued in planned expansion cohorts. This is especially important given the broad expression of IGF-1R across multiple tumor types.”  

For additional detail about the study, please visit https://clinicaltrials.gov/ct2/show/NCT03746431.

About FPI-1434

FPI-1434 is a radioimmunoconjugate designed to target and deliver alpha emitting medical isotopes to cancer cells expressing IGF-1R, a receptor that is overexpressed on many tumor types. FPI-1434 utilizes Fusion’s Fast-Clear linker to connect a human monoclonal antibody that targets IGF-1R with actinium-225, a powerful alpha-emitting isotope with desirable half-life and decay chain properties.

Acknowledgement of US DOE and Actiunium-225 Supply

The actinium-225 used in this research was supplied by the United States Department of Energy Office of Science by the Isotope Program in the Office of Nuclear Physics.

About Fusion
Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Employing a proprietary Fast-Clear linker technology, Fusion connects alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha emitting payloads to tumors. Fusion’s lead program, FPI-1434, is currently in a Phase 1 clinical trial.

Forward-Looking Statements
Certain statements set forth in this press release constitute “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements can be identified by terms such as “believes,” “expects,” “plans,” “potential,” “would” or similar expressions and the negative of those terms. Such forward-looking statements involve substantial risks and uncertainties that could cause Fusion’s research and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including Fusions’ programs’ early stage of development, the process of designing and conducting and clinical trials, , risks relating to business interruptions resulting from the coronavirus (COVID-19) disease outbreak or similar public health crises and other matters that could affect the sufficiency of existing cash to fund operations. Fusion undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the company in general, see Fusion’s quarterly report on Form 10-Q for the quarter ended September 30, 2020 which is available on the Security and Exchange Commission’s website at www.sec.gov and Fusion’s website at www.fusionpharma.com

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/fusion-pharmaceuticals-initiates-multi-dose-portion-of-phase-1-trial-of-fpi-1434-in-patients-with-advanced-solid-tumors-301190376.html

SOURCE Fusion Pharmaceuticals Inc.

IIROC Trade Resumption – ET

Canada NewsWire

TORONTO, Dec. 10, 2020 /CNW/ – Trading resumes in:

Company: Evertz Technologies Limited

TSX Symbol: ET

All Issues: Yes

Resumption (ET): 8:00 AM

IIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. IIROC is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada.

SOURCE Investment Industry Regulatory Organization of Canada (IIROC) – Halts/Resumptions